02:18:16 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandDanmark
ListaMid Cap Copenhagen
SektorHälsovård
IndustriBioteknik
Zealand Pharma är ett bioteknikbolag. Särskilt fokus återfinns inom utvecklingen av läkemedel för behandling av diabetes och diverse tarmsjukdomar. Bolaget innehar en varierad produktportfölj med separata varumärken som säljs på global nivå. Störst verksamhet finns inom den nordiska marknaden. Zealand Pharma grundades 1997 och har sitt huvudkontor i Söborg.

Kalender

2020-11-12 Kvartalsrapport 2020-Q3
2020-08-13 Kvartalsrapport 2020-Q2
2020-05-14 Kvartalsrapport 2020-Q1
2020-04-03 Ordinarie utdelning ZEAL 0.00 DKK
2020-04-02 Årsstämma 2020
2020-03-12 Bokslutskommuniké 2019
2019-11-14 Kvartalsrapport 2019-Q3
2019-08-15 Kvartalsrapport 2019-Q2
2019-05-16 Kvartalsrapport 2019-Q1
2019-04-05 Ordinarie utdelning ZEAL 0.00 DKK
2019-04-04 Årsstämma 2019
2019-03-07 Bokslutskommuniké 2018
2018-11-15 Kvartalsrapport 2018-Q3
2018-08-16 Kvartalsrapport 2018-Q2
2018-05-16 Kvartalsrapport 2018-Q1
2018-04-20 Ordinarie utdelning ZEAL 0.00 DKK
2018-04-19 Årsstämma 2018
2018-03-07 Bokslutskommuniké 2017
2017-11-08 Kvartalsrapport 2017-Q3
2017-08-24 Kvartalsrapport 2017-Q2
2017-05-17 Kvartalsrapport 2017-Q1
2017-04-06 Ordinarie utdelning ZEAL 0.00 DKK
2017-04-05 Årsstämma 2017
2017-03-15 Bokslutskommuniké 2016
2016-11-09 Kvartalsrapport 2016-Q3
2016-08-25 Kvartalsrapport 2016-Q2
2016-05-18 Kvartalsrapport 2016-Q1
2016-04-20 Ordinarie utdelning ZEAL 0.00 DKK
2016-04-19 Årsstämma 2016
2016-03-16 Bokslutskommuniké 2015
2015-11-05 Kvartalsrapport 2015-Q3
2015-08-28 Kvartalsrapport 2015-Q2
2015-05-22 Kvartalsrapport 2015-Q1
2015-04-22 Ordinarie utdelning ZEAL 0.00 DKK
2015-04-21 Årsstämma 2015
2015-03-12 Bokslutskommuniké 2014
2014-03-21 Ordinarie utdelning ZEAL 0.00 DKK
2013-04-30 Ordinarie utdelning ZEAL 0.00 DKK
2012-04-26 Ordinarie utdelning ZEAL 0.00 DKK
2012-04-25 Årsstämma 2012
2011-04-29 Ordinarie utdelning
2020-05-29 22:01:00

Company announcement – No. 30 / 2020

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

Copenhagen, May 29, 2020 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no. 20045078) has received information on transactions in Zealand's shares or related securities conducted by persons discharging managerial responsibilities and/or their closely associated persons and hereby publishes the information on such transactions.

Please see the attached files.

# # #

About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, development, and commercialization of next generation peptide-based medicines that change the lives of people living with metabolic and gastrointestinal diseases. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market. Zealand’s robust pipeline of investigational medicines includes three candidates in late stage development, and one candidate being reviewed for regulatory approval in the United States. Zealand markets V-Go®, an all-in-one basal-bolus insulin delivery option for people with diabetes. License collaborations with Boehringer Ingelheim and Alexion Pharmaceuticals create opportunity for more patients to potentially benefit from Zealand-invented peptide therapeutics.

Zealand was founded in 1998 in Copenhagen, Denmark, and has presence throughout the U.S. that includes key locations in New York, Boston, and Marlborough (MA). For more information about Zealand’s business and activities, please visit www.zealandpharma.com.  

For further information, please contact:

Zealand Pharma Investor Relations
+45 50 60 38 00
investors@zealandpharma.com

Lani Pollworth Morvan, Investor Relations and Communication
LMorvan@zealandpharma.com